The play Abans que arribi l’alemany, about Alzheimer’s, and a flash talks session about Parkinson’s, bring neurodegenerative diseases closer to the public.
IDIBELL joins Brain Week with two scientific dissemination proposals Read More »
The Flow Cytometry Platform of the IDIBELL Scientific-Technical Services incorporated new high-performance equipment. It is the Beckman Coulter CytoFLEX SRT Benchtop Cell Separator. The arrival of this state-of-the-art equipment covers the need to renew the cell separation service and makes new and current technological improvements available to researchers. CytoFLEX SRT can meet the requirements for
Presentation of the new cell sorter of the flow cytometry platform Read More »
The androgen receptor is the main target in the fight against prostate cancer. The study, published in the journal Science Advances, states that the analyzed mutations affect several functional regions of the union domain of the androgen receptor to testosterone.
Yesterday, this association from Sant Joan Despí organized an event in which Dr. Sonia Pernas from IDIBELL and the ICO presented the current situation of breast cancer research.
The DACMA Association donates 10,000 euros for breast cancer research Read More »
This is the main conclusion of a study published in the scientific journal ‘European Respiratory Review’ in which the head of the IDIBELL Tobacco Control research group and head of the Tobacco Control Unit of the Catalan Institute of Oncology, Esteve Fernández, has participated. The article analyzes the results in this field in the different reports presented to date.
Smoking increases the risk of developing severe COVID by 30 to 50% Read More »
The IDIBELL projects by Elisa Espinet, Juan José Rojas, Carolina M. Florian, and Victor Moreno have been selected. All of them presented this Monday in an act with a round table of the most outstanding grants and a dialogue between doctor and patient.
The results show that patients with this disorder have abnormal genetic and epigenetic patterns, which could contribute to the development of diverse clinical manifestations, such as compromise the ability of blood cell production.
“These results reactivate the option of clinical trials with Denosumab in breast cancer selected patients”, says Eva González-Suarez, CNIO and IDIBELL researcher and lead author.
These are the results of an international study with the participation of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Valencian Institute of Oncology (IVO) and in which they make a comparison between the two techniques.
Through a mobile device, HearO™ makes it possible to predict possible complications in patients with heart failure through speech, detect disease-related fluid accumulation and alert the doctor before hospitalization
